We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is This the Right Time to Hold EYE Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
America's Best brand is fueling EYE's growth, aided by managed care and exclusive partnerships.
National Vision's transformation targets exam access, personalization, and mid-single-digit sales growth.
EYE's high expenses and a weak solvency position pose challenges amid ongoing macroeconomic pressures.
National Vision Holdings, Inc.’s (EYE - Free Report) America's Best brand is boosting revenues, leveraging the ongoing strength of managed care. Favorable optical retail industry statistics bode well for the company’s growth potential in the upcoming quarters. Meanwhile, a weak solvency position and escalating expenses pose concerns for National Vision’s operations.
Year to date, this Zacks Rank #3 (Hold) company’s shares have risen 75.6% against the industry’s 3.4% decline. The S&P 500 composite has risen 9.3%.
The leading optical retailer has a market capitalization of $1.81 billion. National Vision beat on earnings in each of the trailing four quarters, delivering an average surprise of 81.81%.
Tailwinds for EYE
Owned & Host Gaining Market Share: The larger of the two brands, America’s Best, is particularly driving revenues, banking on the ongoing strength in Managed Care. The brand introduced the Wise Buys promotion to enhance value offerings and attract new customers. It also launched a new entry progressive bundled offer that provides an ongoing everyday value. Also, America’s Best became the exclusive U.S. retail partner of the Florence by Mills eyewear collection and launched an exclusive partnership with Pair Eyewear nationwide.
National Vision leverages remote capabilities to expand examining capacity, with approximately two-thirds of its store base now enabled with remote technology. The company’s hybrid remote pilot, launched last year, enables in-store optometrists to perform exams in other stores based on availability and demand.
The Owned & Host segment delivered 3.1% comparable store sales growth in the first quarter of 2025, marking its strongest quarterly performance since 2021.
Ongoing Strategic Transformation: The company has been undergoing strategic transformation to address the emergent optometrist shortage through actions like enhanced flexibility, recruiting improvements and the implementation of remote examining capability. Under its new strategy, the company is focusing on heightened segmentation, personalization, and digitization in messaging, product, pricing architecture and customer experience, especially for three customer cohorts — managed care, progressive and outside Rx customers. In the first quarter of 2025, strong continued growth across all three cohorts resulted in a return to mid-single-digit comparable sales growth and solid bottom-line results. Furthermore, steady exam-to-eyeglass purchase conversions and a healthy Net Promoter Score indicate that the company’s pricing actions were accepted by customers.
Headwinds for EYE
Weak Solvency: National Vision exited the first quarter with cash and cash equivalents of $80 million and short-term debt of $101.5 million. This is not good news in terms of the company’s solvency position, particularly during times of macroeconomic headwinds, when it mainly faces supply issues globally.
Image Source: Zacks Investment Research
Mounting Expenses: The overall economic environment continues to be challenging and macroeconomic factors such as inflation and geopolitical uncertainties could indirectly affect National Vision’s results of operations. Actions, such as the ongoing changes in U.S. trade policy and retaliatory tariffs, have led to significant volatility and uncertainty in global markets. These factors continue to weigh on its profitability. In the first quarter of 2025, SG&A expenditures rose 6.4% year over year.
EYE Stock Estimate Trend
The Zacks Consensus Estimate for National Vision’s 2025 earnings per share (EPS) has remained unchanged at 62 cents in the past 30 days.
The Zacks Consensus Estimate for 2025 revenues is pegged at $1.94 billion, suggesting a 2.9% improvement from the year-ago reported number.
Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry’s 9.9% rise. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry’s 3.3% decline in the past year.
Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry’s -10.1%. Shares of the company have surged 129.7% compared with the industry’s 35.9% gain. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched on one occasion and missed on another, the average surprise being 2.8%.
Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 3.8% growth. Shares of the company have rallied 25.9% against the industry’s 14.4% decline. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is This the Right Time to Hold EYE Stock in Your Portfolio?
Key Takeaways
National Vision Holdings, Inc.’s (EYE - Free Report) America's Best brand is boosting revenues, leveraging the ongoing strength of managed care. Favorable optical retail industry statistics bode well for the company’s growth potential in the upcoming quarters. Meanwhile, a weak solvency position and escalating expenses pose concerns for National Vision’s operations.
Year to date, this Zacks Rank #3 (Hold) company’s shares have risen 75.6% against the industry’s 3.4% decline. The S&P 500 composite has risen 9.3%.
The leading optical retailer has a market capitalization of $1.81 billion. National Vision beat on earnings in each of the trailing four quarters, delivering an average surprise of 81.81%.
Tailwinds for EYE
Owned & Host Gaining Market Share: The larger of the two brands, America’s Best, is particularly driving revenues, banking on the ongoing strength in Managed Care. The brand introduced the Wise Buys promotion to enhance value offerings and attract new customers. It also launched a new entry progressive bundled offer that provides an ongoing everyday value. Also, America’s Best became the exclusive U.S. retail partner of the Florence by Mills eyewear collection and launched an exclusive partnership with Pair Eyewear nationwide.
National Vision leverages remote capabilities to expand examining capacity, with approximately two-thirds of its store base now enabled with remote technology. The company’s hybrid remote pilot, launched last year, enables in-store optometrists to perform exams in other stores based on availability and demand.
The Owned & Host segment delivered 3.1% comparable store sales growth in the first quarter of 2025, marking its strongest quarterly performance since 2021.
Ongoing Strategic Transformation: The company has been undergoing strategic transformation to address the emergent optometrist shortage through actions like enhanced flexibility, recruiting improvements and the implementation of remote examining capability. Under its new strategy, the company is focusing on heightened segmentation, personalization, and digitization in messaging, product, pricing architecture and customer experience, especially for three customer cohorts — managed care, progressive and outside Rx customers. In the first quarter of 2025, strong continued growth across all three cohorts resulted in a return to mid-single-digit comparable sales growth and solid bottom-line results. Furthermore, steady exam-to-eyeglass purchase conversions and a healthy Net Promoter Score indicate that the company’s pricing actions were accepted by customers.
Headwinds for EYE
Weak Solvency: National Vision exited the first quarter with cash and cash equivalents of $80 million and short-term debt of $101.5 million. This is not good news in terms of the company’s solvency position, particularly during times of macroeconomic headwinds, when it mainly faces supply issues globally.
Image Source: Zacks Investment Research
Mounting Expenses: The overall economic environment continues to be challenging and macroeconomic factors such as inflation and geopolitical uncertainties could indirectly affect National Vision’s results of operations. Actions, such as the ongoing changes in U.S. trade policy and retaliatory tariffs, have led to significant volatility and uncertainty in global markets. These factors continue to weigh on its profitability. In the first quarter of 2025, SG&A expenditures rose 6.4% year over year.
EYE Stock Estimate Trend
The Zacks Consensus Estimate for National Vision’s 2025 earnings per share (EPS) has remained unchanged at 62 cents in the past 30 days.
The Zacks Consensus Estimate for 2025 revenues is pegged at $1.94 billion, suggesting a 2.9% improvement from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , Hims & Hers Health (HIMS - Free Report) and Cencora (COR - Free Report) .
Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry’s 9.9% rise. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry’s 3.3% decline in the past year.
ALGN sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry’s -10.1%. Shares of the company have surged 129.7% compared with the industry’s 35.9% gain. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched on one occasion and missed on another, the average surprise being 2.8%.
Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 3.8% growth. Shares of the company have rallied 25.9% against the industry’s 14.4% decline. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.